Alzamend Neuro(ALZN) - 2026 Q3 - Quarterly Report

Clinical Development - Alzamend Neuro's lead product candidate, AL001, is in clinical development for Alzheimer's, bipolar disorder, major depressive disorder, and PTSD, with a maximum tolerated dose identified at 240 mg three times daily [118]. - The Phase IIA clinical trial for AL001 was completed in March 2023, with positive topline data announced in June 2023 and full data set expected in October 2024 [117]. - AL001 demonstrated lower plasma lithium levels compared to lithium carbonate while achieving higher lithium concentrations in brain tissues, suggesting a safer therapeutic profile [124]. - The company plans to initiate five clinical trials to compare lithium levels in the brain between AL001 and marketed lithium salts, aiming for lower doses with equivalent therapeutic benefits [122]. - ALZN002, an immunotherapy vaccine for Alzheimer's, received FDA's "study may proceed" letter in October 2022, with a Phase I/IIA trial initiated in April 2023 [127][128]. - The primary goal of the ALZN002 trial is to determine an appropriate dose for a larger Phase IIB efficacy and safety clinical trial [128]. - The collaboration with Massachusetts General Hospital for clinical trials emphasizes the company's commitment to advancing its therapeutic candidates [122]. Financial Performance - Total operating expenses for the three months ended January 31, 2026, were $2.2 million, a 112% increase from $1.0 million in the same period of 2025 [1]. - Research and development expenses for the three months ended January 31, 2026, were $1.3 million, up 186% from $447,000 in 2025, primarily due to increased clinical trial fees [3]. - Clinical trial fees increased to $1.0 million for the three months ended January 31, 2026, compared to $298,000 in 2025, reflecting the AL001 Phase IIB clinical study [5]. - General and administrative expenses for the three months ended January 31, 2026, were $919,000, a 56% increase from $590,000 in 2025 [7]. - The net loss for the three months ended January 31, 2026, was $2.2 million, a 112% increase from $1.0 million in 2025 [1]. - No revenue was generated during the three months ended January 31, 2026, and 2025, with no anticipated revenue for the foreseeable future [2]. - For the nine months ended January 31, 2026, total operating expenses were $5.9 million, a 76% increase from $3.4 million in 2025 [1]. - Research and development expenses for the nine months ended January 31, 2026, were $3.2 million, a 231% increase from $1.0 million in 2025 [6]. - Clinical trial fees for the nine months ended January 31, 2026, were $2.7 million, up 544% from $422,000 in 2025 [8]. - The net loss for the nine months ended January 31, 2026, was $5.9 million, a 75% increase from $3.4 million in 2025 [1]. - Professional fees increased to $1.0 million for the nine months ended January 31, 2026, compared to $433,000 in the same period of 2025, primarily due to higher legal fees related to litigation [153]. - Insurance expenses decreased to $177,000 in the nine months ended January 31, 2026, from $199,000 in the same period of 2025 [154]. - Stock-based compensation expense decreased to $84,000 for the nine months ended January 31, 2026, down from $244,000 in 2025, due to fewer stock options vesting [155]. - Marketing fees decreased to $200,000 for the nine months ended January 31, 2026, compared to $344,000 in the same period of 2025 [156]. - The company reported a net loss of $5.9 million for the nine months ended January 31, 2026, compared to a net loss of $5.3 million in the same period of 2025 [158]. - As of January 31, 2026, the company had cash of $2.7 million and an accumulated deficit of $64.4 million [158]. - Net cash used in operating activities was $5.3 million for the nine months ended January 31, 2026, primarily due to the net loss [164]. - Net cash provided by financing activities was $4.0 million from the sale of Series C Convertible Preferred Stock during the nine months ended January 31, 2026 [166]. - The company anticipates needing substantial additional funding for clinical development activities and ongoing operations [159]. - The company has incurred recurring losses and does not expect to generate sufficient cash flows from operations in the near term [157]. Strategic Goals - Alzamend Neuro is pursuing additional capital to fund ongoing clinical trials and operations, indicating a need for further financing [129][130]. - The company aims to expand its pipeline to include additional indications for AL001 and optimize its value in major markets [120]. - AL001 is designed to mitigate the regulatory burden for safety data due to the well-characterized human toxicology of lithium, which has been marketed for over 35 years [116].